Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI – Get Free Report ) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 134,400 shares, an increase of 278.6% from August 31st’s total of 35,500 shares. Based on an average trading volume of 224,800 shares, the short interest rate is currently 0.6 days. Currently, 4.1% of the company’s shares are short sold.

Biofrontera stock down 2.4%

BFRI traded down $0.03 during trading on Wednesday, reaching $1.23. The company’s stock had a trading volume of 309,691 shares, compared to its average volume of 368,724. The firm has a fifty day simple moving average of $1.17 and a two hundred day simple moving average of $1.26. Biofrontera has a 1 year low of $0.61 and a 1 year high of $9.52. The company has a market cap of $6.26 million, a price-to-earnings ratio of -0.09 and a beta of 0.46.

Biofrontera (NASDAQ:BFRI – Get Your Free Report ) last posted its earnings results on Wednesday, August 14th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.07. The firm had revenue of $7.84 million during the quarter, compared to the consensus estimate of $9.02 million. Biofrontera had a negative net margin of 38.34% and a negative return on equity of 837.97%. As a group, equities analysts forecast that Biofrontera will post -3.11 EPS for the current fiscal year.

Changes in Analyst Ratings

Separately, Benchmark restated a “buy” rating and issued a $7.00 target price on shares of Biofrontera in a research note on Friday, August 16th.

Get the latest stock report on Biofrontera

Hedge funds influence Biofrontera

A hedge fund recently bought a new stake in Biofrontera shares. Rosalind Advisors Inc. acquired a new stake in Biofrontera Inc. (NASDAQ:BFRI – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera makes up about 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned 9.91% of Biofrontera as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.08% of the company’s shares.

About Biofrontera

(Get a free report)

Biofrontera Inc, a biopharmaceutical company, is engaged in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used to treat actinic keratoses, which are precancerous skin lesions, as well as impetigo, a bacterial skin infection.

Featured stories

Get news and reviews for Biofrontera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biofrontera and related companies with MarketBeat.com’s FREE daily email newsletter.